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Abstract 
Plasma heart failure (HF) biomarkers, like natriuretic peptides, are important in diagnosis, prognosis and 
HF treatment. Several novel HF biomarkers have been identified, including Gal-3, GDF-15 and TIMP-1, 
but their clinical potential remains vague. Here we investigated plasma biomarker levels in relation to 
tissue expression and structural and functional cardiac changes. 
Methods: Cardiac remodeling, cardiac function, and plasma and tissue biomarker levels were 
investigated in mice after myocardial infarction induced by temporal and permanent LAD ligation (tLAD 
and pLAD). In addition, a pressure overload model induced by transverse aortic constriction (TAC) and 
an obese/hypertensive HFpEF-like mouse model were investigated.  
Results: Plasma levels of ANP and its cardiac expression were strictly associated with cardiac 
remodeling and function. Gal-3, GDF-15 and TIMP-1 cardiac expressions were also related to cardiac 
remodeling and function, but not their plasma levels. Only directly after myocardial infarction could 
elevated plasma levels of Gal-3 and TIMP-1 be detected. Eight weeks after infarction, plasma levels were 
not elevated despite enhanced cardiac expression and low EF (18.3±3.3%, pLAD). Plasma levels of TIMP-1 
and GDF-15 were elevated after TAC, but this also correlated with increased lung expression and 
congestion. In obese-hypertensive mice, elevated plasma levels of Gal-3, GDF-15 and TIMP1 were 
associated with increased adipose tissue expression and not with cardiac function.  
Conclusions: The Gal-3, GDF-15 and TIMP-1 plasma pool levels are hardly influenced by dynamic 
changes in cardiac expression. These biomarkers are not specific for indices of cardiac remodeling, but 
predominantly reflect stress in other affected tissues and hence provide health information beyond the 
heart. 
Key words: heart failure, cardiac remodeling, biomarker, Galectin-3, GDF-15, TIMP-1 
Introduction 
Standard clinical examination of heart failure 
(HF) patients does not provide means for detailed 
patient stratification and therefore other tools are 
needed. Plasma biomarkers provide great promise to 
further dissect the underlying disease processes, may 
aid in further stratification and allow tailored therapy 
for HF patients [1]. 
Natriuretic peptides are the gold standard HF 
plasma biomarkers, have improved the management 









in the American Heart Association (AHA) and 
European Society of Cardiology (ESC) HF guidelines 
[2, 3]. These peptides are mainly produced and 
released by the heart in response to sustained wall 
stretch [4]. Cardiac-specific troponins were originally 
used as acute damage markers in diagnosis of 
myocardial infarction, but with the appearance of 
high-sensitivity troponin (hsTn) assays are now also 
being used as HF markers and are mentioned in the 
HF guidelines. Most other novel HF biomarkers 
appear to be non-cardiac specific [5]. Hence, the 
diagnostic value of these biomarkers is limited, but 
these biomarkers could provide essential information 
about underlying biological processes, like fibrosis, 
and aid in additive risk stratification of HF patients 
[6]. For this purpose, Gal-3 (Galectin-3) and sST2 
(soluble suppression of tumorogenicity-2) have been 
included in the AHA HF guidelines [3]. Gal-3 is 
associated with organ fibrosis, including cardiac 
fibrosis, and is elevated in HF patients [4, 7, 8, 9]. sST2 
is a soluble decoy receptor for IL-33 and is associated 
with adverse cardiac remodelling, including 
hypertrophy and fibrosis, by inhibiting the protective 
effects of IL-33 [10]. Although not yet mentioned in 
the HF guidelines, many other biomarkers have been 
identified that could act as prognostic biomarkers in 
HF [11]. The fibrotic marker TIMP-1 (tissue inhibitor 
of metalloproteinase-1), for instance, is elevated in HF 
[12-14] and increased levels were detected in coronary 
sinus blood, suggesting cardiac origin [15]. GDF-15 
(growth differentiation factor-15), another emerging 
biomarker, is elevated in HF patients and protects the 
heart from cardiac damage [16-19]. Most interestingly, 
these biomarkers are also elevated in patients with HF 
with preserved ejection fraction (HFpEF), are related 
to disease severity and can have predictive power 
[20-25]. The correlation between the plasma levels of 
the above mentioned novel biomarkers and the 
presence and severity of cardiac dysfunction, and the 
relation to their production in other tissues, is, 
however, largely unknown. Understanding the origin 
of plasma biomarkers and whether other organs or 
tissues contribute to their elevated levels is therefore 
needed.  
In contrast to clinical HF studies, preclinical 
animal studies allow us to investigate biomarkers at 
multiple levels (RNA and protein) and within 
multiple organs and tissues. Nevertheless, biomarker 
studies in small animals are hampered by the small 
plasma/serum volumes and the lack of appropriate 
reagents. We therefore focused on three novel heart 
failure biomarkers, Gal-3, GDF-15, and TIMP-1 and 
the established HF biomarker ANP, for which suitable 
reagents were available. We studied them in three 
mouse models of cardiac remodeling, including two 
models of HF with reduced ejection fraction (HFrEF), 
consisting of a myocardial infarction model and a 
transverse aortic constriction (MI and TAC), and one 
model with HFpEF characteristics generated by high 




All animal experimental protocols were 
approved by the Animal Care and Use Committee of 
University of Groningen, The Netherlands (permit 
numbers: DEC6827A, DEC6920A and 
IVD16487-03-01) and were conducted according to the 
existing guidelines for the care and use of laboratory 
animals. Approximately 10-week-old male C57BL/6J 
mice were obtained from Envigo, the Netherlands. 
Mice were housed on a 12 h light/ 12 h dark cycle 
with ad libitum access to chow and water. In these 
exploratory studies, mice were randomized based on 
bodyweight. Exclusion criteria included abnormal 
bodyweight (>2 SD) and abnormal behavior. Prior to 
surgery, mice received a subcutaneous injection of 
Carprofen (5.0 mg/kg) to alleviate wound pain. For 
anesthesia, 2% isoflurane/oxygen was used. Cardiac 
functional measurements (MRI and pressure loops) 
were performed in a blinded fashion by an 
independent operator. Molecular and histological 
analyses were blinded. No mice were excluded from 
analysis, except for those mice that died or reached a 
humane endpoint before the end of the experiment.  
Myocardial infarction 
Myocardial infarctions (MI) were induced as 
previously described [26]. In brief, mice were 
anesthetized, intubated and placed supine on a heated 
pad for mechanical ventilation. To create large MIs, 
the left anterior descending coronary artery (LAD) 
was permanently ligated using a suture. To create 
small MIs, a temporal ligation was performed: a 
suture was tied onto a polyethylene tube placed on 
the LAD coronary artery and was removed again after 
60 min. Control mice were sham operated. The 
experimental set-up is outlined in Figure S1A. 
TAC  
Transverse aortic constriction (TAC) was 
performed as previously described [26, 27]. In brief, 
mice were anesthetized, intubated and placed supine 
on a heated pad for mechanical ventilation. A suture 
was tied around a blunt 27-gauge needle placed on 
the aortic arch between the branchiocephalic and left 
carotid arteries, establishing a reproducible aortic 
stenosis. Control mice were sham operated. No 
differences were observed between 4 and 8 weeks 





sham-operated mice and these groups were therefore 
combined in later analyses. The experimental set-up is 
outlined in Figure S1B. 
Obesity/hypertension 
Mice were fed high-fat diet (HFD) (60 kcal% fat, 
D12492, Research diets, USA) or a control diet 
indicated with LFD (low fat diet) (10 kcal% fat, 
D12450J, Research diets, USA) for a period of 16 
weeks. After 12 weeks, the diet was supplemented 
with a 4 week infusion of either angiotensin II (AngII) 
(1 mg/kg/day; Bachem, Switzerland) or saline using 
osmotic minipumps (Alzet 1004, Durect corporation, 
USA). Pumps were combined with 
polyetheretherketone tubing (Alzet PEEK tubing 
0002612, Durect corporation, USA) to allow magnetic 
resonance imaging (MRI). Placement of pumps was 
performed as described before [7]. In brief, mice were 
anesthetized and placed in the prone position on a 
heating pad. A subcutaneous pocket was created in 
the right flank for pump insertion. The experimental 
set-up is outlined in Figure S1C. 
Body mass composition 
In the obesity/hypertension model, body mass 
composition was determined after 15 weeks of diet 
intervention using a minispec LF90II body 
composition analyzer (Bruker Optics, USA).  
Magnetic resonance imaging (MRI) 
Cardiac MRI was performed on anaesthetized 
mice using a 9.4 T, 89 mm bore size magnet equipped 
with 1500 mT/m gradients and connected to an 
advanced 400 MR system (BrukerBiospin, Germany) 
as previously described [26, 28]. Images were 
reconstructed and left ventricular end-diastolic 
volume (LVEDV), left ventricular end-systolic volume 
(LVESV) and left ventricular (LV) mass were 
determined using QMass software (version MR 
6.1.5, Medis Medical Imaging Systems, the 
Netherlands) and stroke volume (SV) and ejection 
fraction (EF) were calculated. 
Hemodynamic measurements and sacrifice 
Prior to sacrifice, hemodynamic measurements 
were performed using a Millar pressure transducer 
catheter (Mikro-Tip pressure catheter 1.4F, Transonic 
Scisense, Transonic Europe, The Netherlands). Mice 
were anaesthetized and the catheter was inserted via 
the right carotid artery. Heart rate, arterial pressures, 
left ventricular end-systolic pressure (LVESP), left 
ventricular end-diastolic pressure (LVEDP) and 
maximal and minimum rates of pressure change 
during contraction and relaxation, respectively 
dP/dtmax and dP/dtmin, were recorded. The dP/dtmax 
and dP/dtmin values were adjusted for LV maximal 
pressure (Pmax). After catheter removal, blood was 
collected, transferred into ethylenediaminetetraacetic 
acid (EDTA) tubes and immediately centrifuged at 
1500×g for 10 min, followed by plasma collection. 
Organs were flushed with 10 mL saline to remove 
remaining red blood cells. Thereafter, LV and other 
tissues were collected. Blood plasma and tissues were 
frozen in liquid nitrogen and stored at -80 °C. An LV 
mid-slice of each heart was fixed in formalin and 
processed for histology and immunohistochemistry. 
Immunohistochemistry  
Formalin-fixed paraffin-embedded mid-trans-
verse LV sections were cut in 4 µm thick slices and 
stained with Masson’s trichrome to detect fibrosis. 
Whole stained sections were automatically imaged 
using a Nanozoomer 2.0 HT (Hamamatsu, Japan). 
Fibrosis fraction as a percentage of the entire section 
was quantified from a 20× magnification (ScanScope, 
Aperial Technologies, USA).  
For ANP staining, paraffin sections were 
deparaffinized and, after blocking endogenous 
peroxidases with H2O2, these sections were incubated 
for 1 h at room temperature with rabbit anti-ANP 
(ab91250, ABCAM, UK) in PBS with 1% BSA. For 
Gal-3 staining, antigen retrieval was performed with 
10 mM citrate buffer (pH 6.0) on deparaffinized 
sections and, after blocking endogenous peroxidases 
with H2O2, these sections were incubated for 1 h at 
room temperature with rat anti-Mac2 (CL8942AP, 
Cedarlane, Canada) in PBS with 1% BSA. For ANP, 
goat anti-rabbit IgG/HRP was used as secondary 
antibody and rabbit anti-goat IgG/HRP as tertiary 
antibody. For Gal-3, rabbit-anti rat IgG/HRP was 
used as secondary antibody. Subsequently 3, 
3–diaminobenzidine (DAB) staining was performed 
and thereafter haematoxilin counterstaining, followed 
by mounting using DPX mounting medium 
(Sigma-Aldrich, USA). For microscopy, an Olympus 
BX50 microscope (Olympus, Japan) was used with 4×, 
10× and 20× objectives and images were collected 
with an Olympus DP70 camera (Olympus, Japan). 
RT-qPCR 
Total RNA was isolated from organs using 
TRIzol reagent (Invitrogen Corporation, the 
Netherlands) and from visceral adipose tissue (VAT) 
using RNeasy lipid tissue mini kits (Qiagen, the 
Netherlands). cDNA was synthesized using 
QuantiTect Reverse Transcription kits (Qiagen, The 
Netherlands). RNA concentration of samples was 
determined by spectrophotometry (NanoDrop 2000, 
ThermoScientific, the Netherlands). Gene expression 
levels were determined using Absolute QPCR SYBR 
Green ROX mix (Abgene, Epsom, UK) using 7.5 ng 





cDNA. Real-time quantitative PCR (RT-qPCR) was 
performed on a C1000 Thermal Cycler CFX284 
Real-Time Detection system (Bio-Rad Laboratories, 
The Netherlands). Gene expressions were corrected 
by ribosomal protein, large, P0 (36B4) reference gene 
expression. This gene showed minimal variation in 
expression between tissues, in contrast to many other 
reference genes (B2M, TBP, Ppia, GAPDH and 
PRL13A) that showed at least a 1.5-fold difference 
between LV and one of the tested organs (data not 
shown). Gene expressions in different organs were 
corrected by the values in LV of control mice. 
Oligonucleotide pairs are listed in Table S1. 
ELISA and Western blot analysis of 
biomarkers 
The following commercial enzyme-linked 
immunosorbent assays (ELISA) were used to 
determine protein levels in plasma: Gal-3 (DY1197, 
R&D, USA); GDF-15 (MGD150, R&D, USA); TIMP-1 
(MTM100, R&D, USA); NT-proANP (BI-20892, 
BIOMEDICA, Austria). Plasma biomarker quantities 
are reported per volume of plasma.  
The above-mentioned ELISA kits were also used 
for measurement of Gal-3, GDF-15 and TIMP-1 
protein levels in cardiac, lung and adipose tissue. For 
LV and lung, tissue homogenization was performed 
in phosphate buffered saline (PBS) containing 0.5% 
Triton-x100 (Sigma-Aldrich, USA) and protease 
inhibitor (Roche 11873580001, complete, EDTA-free, 
Sigma-Aldrich, USA). After centrifugation at 12000 ×g 
for 10 min at 4 °C, the supernatants were used. For 
measurement of Gal-3, GDF-15 and TIMP-1 protein 
levels in VAT, total protein was extracted from tissues 
using Minute Total Protein Extraction kits for Adipose 
Tissues/Cultured adipocytes (Invent Biotechnologies, 
USA). Total lysate protein content was determined 
using Pierce BCA protein assay kits (Thermo-
Scientific, USA). Tissue biomarker levels determined 
by ELISA were corrected for total protein lysate. 
The NT-proANP ELISA kit was not suitable for 
detection of ANP in tissue lysates and therefore 
detection of ANP was performed by Western blotting. 
Proteins were isolated from frozen organs 
homogenized in ice-cold lysis buffer (50 mM Tris pH 
8.0, 1% NP40, 0.5% deoxycholate, 0.1% SDS, 150 mM 
NaCl, 1 mM PMSF, 15 mM sodium vanadate) 
supplemented with protease and phosphatase 
inhibitor cocktails (Sigma-Aldrich, USA), and from 
VAT using the Minute Total Protein Extraction kit for 
Adipose Tissues/Cultured adipocytes (Invent 
Biotechnologies, USA). Proteins were loaded on 
SDS-PAGE gels and transferred onto nitrocellulose 
membranes (Bio-Rad, USA). The following antibodies 
were used for immunoblotting: anti-ANP (ab91250, 
Abcam, UK); anti-GAPDH (10R-G109A, Fitzgerald, 
USA); anti-MAC-2 (Gal-3) (Tebu-Bio, The Nether-
lands); anti-rat immunoglobulins/HRP (ab6734, 
Abcam, USA); anti-rabbit immunoglobulins/HRP 
(P0448, Dako, Denmark); and rabbit anti-mouse 
immunoglobulins/HRP (P0260, Dako, Denmark). 
Signals were detected by enhanced chemilumines-
cence (ECL) (PerkinElmer, USA), and intensities of 
bands were quantified with ImageQuant LAS 4000 
(GE Healthcare Eurpe GmbH, Belgium). Protein 
levels were corrected by GAPDH reference protein 
levels. Fold changes relative to internal control were 
calculated and shown. 
Statistics 
All values are presented as mean ± standard 
error of the mean (SEM). Student's paired 
two-tailed t-test was used for two-group comparisons 
and one-way analysis of variance (ANOVA) followed 
by Tukey’s post-hoc correction for multigroup 
comparisons. For non-normally distributed data or 
data without homogeneity of variance, 
non-parametric tests were performed. In this case, 
Mann-Whitney tests were used for two group 
comparisons and Kruskal-Wallis followed by 
Mann-Whitney tests for multiple group comparisons. 
Normality of data and homogeneity of variance were 
tested using the Shapiro-Wilk test for normality and 
Levene’s test for homogeneity of variances, 
respectively. Correlation was determined using 
Spearman’s correlation test. P < 0.05 was considered 
to be significant. SPSS software (IBM SPSS statistics, 
version 22, IBM, USA) was used for statistical 
analyses.  
Results 
Cardiac remodeling and biomarker expression 
after temporal LAD ligation (tLAD)  
Myocardial infarctions (MIs) were generated by 
temporal and permanent ligations of the left anterior 
descending coronary artery (tLAD and pLAD, 
respectively). The tLAD groups were investigated at 
multiple time points, whereas the pLAD group was 
investigated at 8 weeks only (Figure S1A). The effects 
of tLAD in time are presented in Figure 1, and the 
comparison between tLAD and pLAD at 8 weeks is 
shown in Figure 2 and Table 1.  
Serial MRI measurements of the tLAD groups 
revealed a rapid drop in ejection fraction (EF) within 
one week post-MI and histological analysis of LV 
sections by Masson’s trichrome staining confirmed 
the presence of infarcted fibrotic areas (Figure 1A-B). 
Cardiac gene expression of NPPA, encoding ANP, 
increased directly after MI and remained at a similar 





level thereafter (Figure 1C, left panel). Tissue ANP 
levels, determined by Western blotting, were also 
significantly elevated after tLAD (Figure 2C, middle 
panel, and Figure S2) and immunohistochemical 
analysis revealed that ANP was predominantly 
elevated in cardiomyocytes in the non-infarcted area 
(Figure S3). This also resulted in elevated 
NT-proANP plasma levels (Figure 1C, right panel), 
which increased even faster than tissue levels. This 
may be explained by ischemia-induced ANP secretion 
after infarction [29].  
 
 
Figure 1. Cardiac function, remodeling and biomarker expression after tLAD. (A) Percent ejection fraction (EF) after tLAD, as determined by MRI (N=8-10). (B) 
Quantification of percent LV fibrosis as determined by Masson’s trichrome staining (left panel) (N=8-10). Representative images of stained mid-left ventricular slices of mice of 
the 8 weeks group are shown on the left with higher magnifications of the indicated areas at the bottom. (C) NPPA gene expression (left panel), ANP protein levels in LV (middle 
panel) and NT-proANP biomarker plasma levels (right panel). (D-F) The same as (C), but for, respectively (D) Gal-3, (E) GDF-15 and (F) TIMP-1. Gene expression changes were 
corrected for 36B4 and are shown as fold changes relative to the 3 days sham group (N=6-10). ANP protein levels in the LV were determined by Western blot and corrected 
for GAPDH levels. All other proteins were determined by ELISA. Plasma protein levels N=6-9. LV protein levels N=4-9. Bars represent means. Error bars represent SEM. 
*P<0.05 versus respective control group. Black bar in (B) represents 2 mm. 






Figure 2. Cardiac function, remodeling and biomarker expression 8 weeks after tLAD and pLAD. (A) Representative MRI images of short axis in systole and 
diastole (upper panel). EF (%) 8 weeks after tLAD and pLAD, as determined by MRI (N=8-9). (B) Representative images of Masson’s trichrome-stained transverse mid slices of 
LVs after 8 weeks follow up are shown (upper panel). (C) Quantification of percent LV fibrosis (lower panel, N=8-9), NPPA gene expression (left panel), and NT-proANP 
biomarker plasma levels (right panel). (D-F) The same as (C), but for, respectively (D) LGALS3/Gal-3, (E) GDF-15 and (F) TIMP-1 (N=6-10). Gene expression corrected for 36B4 
and shown as fold changes relative to the 8 weeks sham group (N=6-9). Plasma levels N=8-9. Bars represent means. Error bars represent SEM. *P<0.05 versus control group. 
#P<0.05 versus tLAD. Black bar in (B) represents 2 mm. 
 
In contrast to NPPA, gene expression of LGALS3 
(encoding Galectin-3), GDF-15 and TIMP-1 strongly 
increased within 3 days after tLAD, but subsequently 
decreased again, showing only a modest elevation at 8 
weeks (Figure 1D-F, left panels). These gene 
expression profiles were similar to the expression 
profiles of extracellular matrix genes, including 
alpha-1 type 1 collagen (Col1a1) and alpha-3 type 1 
collagen (Col3a1), and inflammatory genes, like 
interleukin-6 (IL-6) (Figure S4A). Gene expression 
changes were specific to the heart and no changes 
were observed in other tissues investigated (lung, 
kidney, liver) (Figure S4B-D). Gal-3, GDF-15 and 
TIMP-1 protein levels in tissue lysates and blood 
plasma were determined by ELISA. LV protein levels 
of Gal-3, GDF-15 and TIMP-1 largely paralleled gene 
expression patterns, with highly elevated protein 
levels within 3 days after MI (Gal-3 ~10-fold; GDF-15 
~3-fold; TIMP-1 ~20-fold increased) and subsequent 
decrease in the weeks thereafter (Figure 1D-F, middle 





panels). Immunohistochemical analysis confirmed 
this strong temporal increase in Gal-3 levels in the 
heart and importantly Gal-3 expression was confined 
to the infarcted area and localized to both 
non-cardiomyocytes and cardiomyocytes (Figure S5). 
The increase in expression also resulted in a temporal 
elevation of blood plasma levels of both Gal-3 and 
TIMP-1 at 3 days post-infarction (Figure 1D, F, right 
panels). None of them remained elevated in the weeks 
thereafter, despite reduced cardiac EF. Thus, only 
highly elevated LV expression directly after tLAD 
resulted in a temporal increase in Gal-3 and TIMP-1 
plasma levels.  
Cardiac remodeling and biomarker expression 
after permanent LAD ligation 
The absence of elevated biomarker plasma levels 
(except NT-proANP) 8 weeks post-tLAD could be due 
to small MIs and hence limited decrease in cardiac 
function (e.g., EF from 58.1±1.6% in control to 
39.0±2.1% in tLAD). Permanent LAD ligations 
(pLAD) that were performed in parallel generated 
much stronger cardiac dilatation at 8 weeks and a 
significant further decrease in EF to 18.3±3.3% (Figure 
2A and Table 1). Moreover, cardiac fibrosis, 
indicative of infarct size, was much more pronounced 
at 8 weeks pLAD as compared to tLAD and the same 
was true for cardiac hypertrophy and diminished 
contraction and relaxation (Figure 2B and Table 1).  
Since cardiac protein levels reflected gene 
expression levels at 8 weeks, only gene expression 
levels are shown for simplicity. For 
comprehensiveness, cardiac protein levels of all 
experiments are included in Figure S6. NPPA gene 
expression was much more elevated in the 8 weeks 
pLAD group as compared to the tLAD group and the 
same was true for cardiac protein levels and plasma 
levels (Figure 2C and Figure S6A). Cardiac gene 
expression and protein levels of Gal-3, GDF-15 and 
TIMP-1 were all higher in pLAD as compared to 
tLAD, but again this did not result in elevated plasma 
levels of these biomarkers (Figure 2D-F and Figure 
S6A). Thus, despite strongly reduced EF (18.3±3.3%) 
and concomitantly elevated cardiac expression, blood 
plasma levels did not change, except for NT-proANP.  
Cardiac remodeling and biomarker expression 
after transverse aortic constriction (TAC) 
To corroborate the above-mentioned findings, 
we decided to include a cardiac hypertrophy model 
by inducing LV pressure overload via transverse 
aortic constriction (TAC) (Figure S1B). In this model, 
EF progressively worsened from 4 to 8 weeks and, as 
expected, induced strong and progressive 
cardiomyocyte hypertrophy (Figure 3A-B). Cardiac 
fibrosis was modestly elevated in this cardiac 
hypertrophy model (Figure S7A) and hemodynamic 
analysis revealed a strong increase in LV end-systolic 
and end-diastolic pressures (LVESP, LVEDP), and 
contractility (dP/dTmax) and relaxation (dP/dTmin) 
worsened after 4 and 8 weeks post-TAC (Table 1).  
Cardiac gene expression and protein levels of all 
four biomarkers were significantly elevated 4 and 8 
weeks after TAC (Figure 3C-F and Figure S4B). In 
plasma, NT-proANP levels were increased in both 
TAC groups. Plasma Gal-3 was again not elevated, 
despite increased cardiac expression and protein 
levels (Figure 3D). However, plasma TIMP-1 was 
clearly elevated and GDF-15 was elevated in the 8 
weeks TAC group only (Figure 3E-F). This suggests 
that the underlying etiology of cardiac remodeling 
rather than cardiac function (e.g., %EF) per se 
determines the plasma levels of these biomarkers. The 
higher cardiac Gal-3, GDF-15 and TIMP-1 protein 
levels in the 8 weeks post-TAC group as compared to 
the post-MI groups are in accordance with this 
suggestion (Figure S6, comparison of panels A and B).  
 
Table 1. Hemodynamic effects and effects on cardiac dimensions and function in tLAD/pLAD, TAC and HFD/AngII mice. 
  P-catheter     MRI   
 HR MAP LVESP LVEDP dP/dtmax dP/dtmin LVEDV LVESV EF 
Sham  519 ± 18 86.7± 0.9 100.3 ± 2.6 7.8 ± 1.4 81.7 ± 4.6 -78.3 ± 5.4 62.5 ± 2.6 26.4 ± 1.9 58.1 ± 1.6 
tLAD  536 ± 9 86.6± 2.1 96.7 ± 3.1 9.4 ± 1.4 72.7 ± 2.4 -63.73 ± 4.0* 80.3 ± 3.8* 49.3 ± 3.6* 39.0 ± 2.1* 
pLAD  489 ± 14 72.3± 3.5*# 84.2 ± 3.8*# 11.6 ± 0.4* 55.9 ± 1.4*# -46.0 ± 1.8*# 175.1 ± 21.7*# 148.2 ± 22.9*# 18.3 ± 3.3*# 
               
Sham 478 ± 18 81.6± 1.3 90.8 ± 3.0 4.3 ± 0.9 82,5 ± 3.9 -85,4 ± 3,6 59.0 ± 1.9 22.6 ± 1.2 62.0 ± 1.1 
TAC4 484 ± 15 91.5± 5.7* 137.4 ± 5.4* 13.9 ± 4.0* 48,8 ± 3.7* -50,0 ± 2,8* 79.1 ± 3.2* 54.5 ± 3.6* 31.5 ± 2.2* 
TAC8  502 ± 9 85.7± 2.7 119.1 ± 9.7* 22.0 ± 2.0* 44,99 ± 1.6* -39,9 ± 1.6* 100.2 ± 6.5*# 77.4 ± 7.0*# 23.6 ± 2.2*# 
               
LFD  485 ± 21 93.6± 3.7 97.3 ± 2.3 10.5 ± 2.0 74.8 ± 4.7 -66.4 ± 6.4 49.9 ± 2.1 22.7 ± 1.8 55.1 ± 1.8 
HFD 472 ± 10 99.9± 2.4 105.1 ± 3.9 17.2 ± 2.7 72.5 ± 4.1 -60.5 ± 3.6 46.3 ± 1.4 17.8 ± 0.7 61.7 ± 0.9* 
HFD+AngII 460 ± 30 107.8± 2.9* 114.1 ± 9.2* 17.7 ± 1.8 59.0 ± 4.8* -47.4 ± 4.1* 51.5 ± 2.5 24.7 ± 3.1 53.7 ± 3.7 
Data are presented as mean ± standard error of the mean. dP/dtmax: maximal left ventricular contraction corrected by maximal ventricular pressure (1/s); dP/dtmin= maximal 
left ventricular relaxation corrected by maximal ventricular pressure (1/s); EF: ejection fraction (%); HFD: high fat diet; HR: heart rate (bpm); MAP: mean arterial pressure 
(mmHg); P-catheter: pressure catheter; MRI: magnetic resonance imaging; LFD: low fat diet; LVESP: left ventricular end-systolic pressure (mmHg); LVEDP: left ventricular 
end-diastolic pressure (mm Hg); LVEDV: left ventricular end-diastolic volume (µl); LVESV: left ventricular end-systolic volume (µl); pLAD: permanent ligation of the left 
anterior descending coronary artery; TAC: transverse aortic constriction; tLAD: temporal ligation of the left anterior descending coronary artery. N=8-12. *P<0.05 versus 
respective control group. #P<0.05 for pLAD versus tLAD, TAC 4 wks versus TAC 8 wks or HFD+AngII versus HFD. 






Figure 3. Cardiac function, remodeling and biomarker expression 4 and 8 weeks after TAC. (A) Representative MRI images of short axis in systole and diastole 
(upper panel). EF (%) 8 weeks after tLAD and pLAD, as determined by MRI. (B) Representative images of mid-ventricular slices stained with FITC-WGA to determine cell size 
(upper panels). Quantification of cell size based on FITC-WGA staining (lower panel). (C) NPPA gene expression (left panel), and NT-proANP biomarker plasma levels (right 
panel). (D-F) The same as (C), but for, respectively (D) LGALS3/Gal-3, (E) GDF-15 and (F) TIMP-1. All analysis N=15-20 for sham, N=8-10 per TAC group. Bars represent 
means. Error bars represent SEM. *P<0.05 versus control group. #P<0.05 versus TAC 4 wks. Red bar in (B) represents 50 µm. 
 
Comparison of biomarker expression in other 
tissues post-MI and post-TAC 
Since cardiac failure can cause stress in distal 
organs, gene expression in other tissues was also 
investigated. As shown in Figure 4 (TAC study) and 
Figure S8 (tLAD and pLAD data), NPPA expression 
was confined to the heart, but the other biomarkers 
showed strong expression in other investigated 
organs (kidney, lung, liver). GDF-15 gene expression 
was about 100-fold higher in the liver and Gal-3 gene 
expression was almost 30-fold higher in lung as 
compared to LV tissue. This indicates that other 
organs may profoundly contribute to the plasma 
levels of these markers.  
Despite reduced EF, no expression changes were 
identified in other organs post-MI (tLAD and pLAD) 
(Figure S8). After TAC, however, elevated 
expressions of Gal-3, GDF-15 and TIMP-1 were 
observed in lung tissue and Gal-3 and GDF-15 also 
showed some increase in the liver (Figure 4A-D). 
Since GDF-15 and TIMP-1 showed the highest fold 
increase in lung, lung protein levels, they were also 
investigated. Although, Gal-3 protein levels did not 
increase in the lungs, GDF-15 and TIMP-1 protein 





levels were significantly elevated (Figure 4E). The 
lung protein levels of GDF-15 and TIMP-1 also 
correlated with plasma protein levels and also with 
lung weight, suggesting that lung congestion in TAC 
animals could stimulate lung expression (Figure 
4F-G). These results indicate that increased plasma 
levels after TAC may involve dynamic contribution of 
other affected organs. No congestion and increased 
lung expression were observed after MI, which could 




Figure 4. Biomarker gene expression in different organs post-TAC and lung-associated protein levels. (A-D) Gene expression levels in LV, liver, kidney and lung 
at 4 and 8 weeks post-TAC. (A) NPPA, (B) LGALS3, (C) GDF-15, (D) TIMP-1. N=15-20 for sham group of TAC experiment. For other groups, N=7-10. Bars represent means. 
Error bars represent SEM. *P<0.05 versus control group. #P<0.05 versus TAC 4wks. (E) Quantification of lung protein levels of Gal-3 (left), GDF-15 (middle) and TIMP-1 
(right). (F) Association between GDF-15 and TIMP-1 plasma levels and their respective lung protein levels. (G) Association between GDF-15 and TIMP-1 lung 
protein levels and lung weight. Points in graph represent individual measurements of combined groups (N=17-25). Spearman’s correlation test was performed. 





Biomarker levels in a high fat/ AngII mouse 
model 
To further investigate the role of underlying 
etiology, we decided to include a mouse model that 
incorporates two important HFpEF risk factors, 
obesity and hypertension (Figure S1C). Compared to 
the control LFD mice, the HFD and HFD/AngII 
groups showed a significant increase in fat mass 
(Figure S9). In none of the tested conditions was 
cardiac dilatation or reduction in cardiac EF observed 
(Figure 5A). Low-dose AngII infusion induced 
cardiac fibrosis (Figure 5B), and cardiac mass 
increased significantly in the HFD+AngII group 
(Table S2). Importantly, in the combined HFD+AngII 
treatment group, cardiac dysfunction was observed, 
including diminished relaxation, indicative of a 
HFpEF-like phenotype (Table 1).  
 
 
Figure 5. Cardiac function, remodeling and biomarker expression in hypertensive/obese mice. (A) Representative cardiac magnetic resonance imaging (MRI) 
images of the short axis of the LFD, HFD and HFD+AngII groups at 16wks. EF (%) as determined by MRI (lower panel). (B) Representative images of Masson’s trichrome-stained 
mid-ventricular sections of the LFD, HFD and HFD+AngII groups. Quantification of percent LV fibrosis (lower panel). (C) NPPA gene expression (left panel), and NT-proANP 
biomarker plasma levels (right panel). (D-F) The same as (C), but for, respectively (D) Gal-3, (E) GDF-15 and (F) TIMP-1. N=7-13. Bars represent means. Error bars represent 
SEM. *P<0.05 versus LFD. #P<0.05 versus HFD. Black bar in (B) represents 2 mm. 





Investigation of LV NPPA gene expression and 
NT-proANP plasma levels revealed that these were 
elevated in the HFD+AngII group, in line with 
observed cardiac remodeling in this group (Figure 
5C). Gal-3, GDF-15 and TIMP-1 were all elevated in 
plasma of the HFD groups, irrespective of AngII 
treatment, and hence plasma levels were not 
associated with cardiac remodeling (Figure 5F-H). In 
the LV, Gal-3 and TIMP-1 gene expressions did not 
change in the HFD group and GDF-15 gene 
expression showed only a moderate elevation, 
indicating that other tissues must be responsible for 
the elevated plasma levels (Figure 5 and Figure S6C). 
In lung and liver, no gene expression changes were 
observed for Gal-3, GDF-15 and TIMP-1 and in 
kidney, minor changes were observed (Figure S10). 
Since adipose tissue was strongly increased in the 
HFD groups, gene and protein expressions were also 
investigated in visceral adipose tissue (VAT). 
Interestingly, Gal-3, GDF-15 and TIMP-1 gene 
expression and proteins were readily detected in VAT 
and, importantly, strongly induced in the HFD 
groups (Figure 6). Gal-3 levels in HFD groups were 
almost 300-fold higher in VAT as compared to LV. 
Importantly, VAT protein levels of Gal-3 and GDF-15 
strongly correlated with plasma biomarker levels 
(Figure S11).  
Discussion 
Here we investigated HF biomarkers ANP, 
Gal-3, GDF-15 and TIMP-1 at three different levels: i) 
organ gene expression, ii) organ protein quantities 
and iii) plasma protein quantities, all in relation to 
cardiac function and structure. This was performed in 
post-MI and TAC HFrEF mouse models and in an 
obese/hypertensive mouse model with HFpEF 
characteristics. Our comprehensive dataset revealed 
that cardiac gene expression and/or protein levels of 
these markers significantly increased upon cardiac 
remodeling. However, in blood plasma, only 
NT-proANP levels were specifically and significantly 
elevated in response to cardiac remodeling in all 
mouse models. Circulating levels of Gal-3, GDF-15 
and TIMP-1 were strongly influenced by extra-cardiac 
tissues and their elevation also reflects enhanced 
stress and concomitant productions in these 
extra-cardiac tissues (Figure 7).  
Cardiac gene expression of all four biomarkers 
paralleled in most cases the cardiac protein levels. 
Changes in cardiac ANP gene expression and protein 
levels showed some divergence under some 
conditions and this may be related to additional levels 
of control, including protein secretion and 
post-translational processing of ANP. Whereas ANP 
cardiac gene expression and plasma levels showed a 
very strong correlation in all cases, this was not true 
for the other biomarkers. At 8 weeks post-MI, cardiac 
expressions of Gal-3, GDF-15 and TIMP-1 were clearly 
elevated, but not their plasma levels. Although 
elevated plasma levels of GDF-15 and TIMP-1 were 
observed 8 weeks post-TAC, this may not simply 
reflect increased GDF-15 and TIMP-1 cardiac 
expression, since in these animals lung expression 
was also clearly elevated. TIMP-1 protein levels in 
lung tissue were even 4.5 times higher as compared to 
LV levels. Taking organ size into consideration, this 
 
 
Figure 6. HF biomarkers in visceral adipose tissue of hypertensive/obese 
mice. Gene expression changes are presented as fold change relative to LV levels in 
the LFD group (dashed lines). (A) NPPA gene expression (left) and ANP protein levels 
(right) in VAT. (B-D) The same for, respectively, (B) Gal-3, (C) GDF-15 and (D) 
TIMP-1. The dashed line shows the levels observed in the LV of the LFD group. 
N=4-10. Bars represent means. Error bars represent SEM. *P<0.05 versus LFD. 
#P<0.05 versus HFD.  





suggests that under these conditions lungs may 
contribute stronger to the elevated plasma levels. The 
expression also correlated with lung weight, 
suggesting that TAC-mediated congestion may be 
responsible for increased GDF-15 and TIMP-1 plasma 
levels. It is therefore tempting to suggest that 
hemodynamic stress in other organs and tissues can 
contribute to elevated plasma levels of these 
biomarkers and hence these markers are indirectly 
associated with cardiac function.  
In contrast to NPPA (ANP), the other biomarkers 
showed a fast temporal increased expression in the 
heart after cardiac infarction that resembled the 
pattern of inflammatory (IL-6) and pro-fibrotic genes 
(Col1a1, Col3a1), which is in accordance with their 
suggested functions in these processes. Whereas Gal-3 
expression was confined to the infarcted area, ANP 
expression was mostly elevated in the remote area 
and absent from the infarcted (fibrotic) regions. 
Although we were unable to stain mouse TIMP-1 and 
GDF-15, the latter has previously been shown to be 
highly expressed in cardiomyocytes in the infarcted 
area in human hearts [30]. Therefore, in contrast to 
ANP, these novel biomarkers appear to play a role in 
the infarcted area, which 
again stresses the differences 
between these markers. 
Furthermore, as shown for 
Gal-3, different cell types 
may be involved at different 
stages after infarction, which 
further adds to the 
complexity of this biomarker.  
The highly elevated 
expressions directly after 
infarction resulted in 
temporally elevated plasma 
levels of Gal-3 and TIMP-1. 
Although Gal-3 and TIMP-1 
plasma levels have been 
reported to be elevated in 
patients with acute MI, the 
exact temporal changes have 
never been systematically 
investigated. Performing 
such clinical investigations 
could be rewarding, but 
results may be more complex 
to interpret. In patients, 
cardiovascular risk factors 
and comorbidities are 
involved in both causing and 
maintaining cardiovascular 
disease, whereas our MI 
mouse model was an isolated 
ischemic model, lacking these 
confounding factors that might influence biomarker 
levels, as discussed below. 
Our observation that the plasma levels of the 
tested novel biomarkers did not change despite 
severely reduced EF (8 weeks post-MI), may sound 
remarkable, but we would like to point out that these 
are otherwise healthy mice without other 
co-morbidities. This seems to reflect the results of the 
HF-ACTION clinical study in which patients of 
NYHA class III and IV were included; but, in order to 
allow them to follow a structured exercise program, 
these patients were generally healthier than patients 
included in other HF studies. Not surprisingly, in this 
study, much lower Gal-3 plasma levels were 
measured as compared to other HF studies [31]. The 
observations that these biomarkers are mostly 
elevated in patients with additional co-morbidities 
and poor outcome further strengthens our 
observations [14, 15, 17, 32]. In particular, we showed 
that Gal-3, GDF-15 and TIMP-1 were strongly 
influenced by obesity. The elevated plasma levels in 
obese animals were not associated with cardiac 
function. Adipose tissue was the major producer of 
 
Figure 7. Model of organ/tissue involvement in plasma biomarker levels. Model with simplified schematic depiction 
of organ/tissue contribution to plasma biomarkers levels. Included organs/tissues: heart, lungs, kidney, liver and visceral 
adipose tissue (VAT). Larger arrow represents stronger relative contribution. 
 





Gal-3 and its levels were even more than 300 times 
higher in adipose tissue as compared to LV tissue. 
Additional induction of a cardiac HFpEF-like 
phenotype in these animals using AngII infusion did 
not result in further enhancement of their plasma 
levels, despite alterations in cardiac expressions. 
Positive associations of these biomarkers have been 
reported with several other diseases and with obesity, 
and this provides clear evidence that non-cardiac 
sources are important determinants of their 
circulating levels in humans as well [5, 33, 34, 35, 36]. 
We therefore would like to postulate that elevated 
levels of these biomarkers in HF patients most likely 
reflect the presence of other comorbidities and hint to 
stress and involvement of other organs.  
In many clinical studies, circulating levels of 
Gal-3, GDF-15 and TIMP-1 have been correlated to HF 
severity based on clinical symptoms (NYHA class) or 
tested for their predictive power for mortality and HF 
rehospitalization in HF patients [12, 14, 20, 21, 32, 34, 
37]. Even though several clinical studies have shown 
that these biomarkers are associated with cardiac 
function (e.g., EF or LV strain) [38], cardiac 
remodeling (e.g., LV dimensions) [39, 40] and 
LV-filling pressures [37, 41, 42], none of these studies 
provided evidence for the cardiac nature of the 
increased systemic levels. Not surprisingly, several 
studies also provided evidence that these biomarkers 
could not be directly related to specific cardiac indices 
in HF patients, including echocardiographic 
parameters [43]. Moreover, in an elegant study, it was 
shown that elevated Gal-3 levels did not decline after 
heart transplantation, a clear indication that 
non-cardiac sources were responsible for high Gal-3 
levels in these HF patients [44]. In cardiomyopathy 
patients, it was recently reported that plasma Gal-3 
levels did not correlate with Gal-3 levels in 
endomyocardial biopsies [45]. Therefore, we postulate 
that correlating circulating biomarker levels to 
parameters of cardiac dysfunction does not take into 
account the above-mentioned issues, and such results 
might therefore generate false results. Thus, although 
these biomarkers are intensely studied in HF, our 
results call into question the feasibility of relating 
plasma/serum biomarkers levels to cardiac-specific 
indices of HF severity including function and 
dimensions. Our data clearly indicate that these 
measures have a strong relation to cardiac biomarker 
expression and production, but not necessarily to 
systemic biomarker levels. 
 Since ANP expression is highly cardiac specific, 
its plasma levels are not obscured by contribution of 
non-cardiac tissues. This is not true for the other HF 
biomarkers studied here and this is most likely also 
true for other non-cardiac specific HF biomarkers. 
Unfortunately, we could not test this for another HF 
biomarker that has been included in the AFFC/AHA 
clinical guidelines, soluble ST2 (sST2), due to lack of 
proper mouse reagents. From literature, it is known 
that sST2 gene expression is not cardiac specific and it 
is therefore likely that non-cardiac contributions will 
also affect plasma levels of sST2 [10, 46, 47]. Our 
results clearly show that it will be important to 
rigorously test any novel plasma biomarker in animal 
models, allowing the simultaneous investigation of 
the dynamic contribution of multiple tissues to the 
plasma levels. 
Conclusion 
In conclusion, we have shown that only plasma 
NT-proANP levels are directly related to cardiac 
function, whereas plasma levels of the novel HF 
biomarkers Gal-3, GDF15 and TIMP-1 are heavily 
influenced by dynamic contribution of non-cardiac 
tissues. Therefore, rather than being specific for 
indices of cardiac remodeling, these biomarkers 
reflect health status beyond cardiac function. They 
also reflect stress in other organs, either as a 
consequence of the failing heart and/or as a 
consequence of other underlying comorbidities, like 
metabolic syndromes.  
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